05 January 2022 | News
PRISM BioLab provides a proprietary library of peptide mimetic small molecules
image credit- shutterstock
PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group.
PRISM BioLab is eligible to receive an upfront payment, success-based milestone payments and royalties on future net sales.
Further, PRISM BioLab is working on new drug targets in collaboration with global and Japanese pharmaceutical companies.